Based on the high density of transmembrane NK-1Rs that tumor cells expressed, several attempts have attempted to utilize peptide vectors based on endogenous NK-1R ligand, SP or its close analogues, and small molecular antagonists, NK-1R vectors, as radiopharmaceuticals in tumor therapy with radionuclides [6,12]. Here, TACR1 is linked to neoplasm.